TOI vs. BDSX, SERA, QIPT, EUDA, PIII, XGN, BNR, ENZ, CCM, and NIVF
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include Biodesix (BDSX), Sera Prognostics (SERA), Quipt Home Medical (QIPT), EUDA Health (EUDA), P3 Health Partners (PIII), Exagen (XGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), Concord Medical Services (CCM), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry.
Oncology Institute vs.
Oncology Institute (NASDAQ:TOI) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Biodesix has lower revenue, but higher earnings than Oncology Institute. Biodesix is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Oncology Institute has a net margin of -17.63% compared to Biodesix's net margin of -66.84%. Oncology Institute's return on equity of -186.83% beat Biodesix's return on equity.
Oncology Institute has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Oncology Institute currently has a consensus price target of $2.50, suggesting a potential upside of 180.93%. Biodesix has a consensus price target of $3.06, suggesting a potential upside of 246.94%. Given Biodesix's higher possible upside, analysts plainly believe Biodesix is more favorable than Oncology Institute.
In the previous week, Oncology Institute and Oncology Institute both had 1 articles in the media. Biodesix's average media sentiment score of 0.97 beat Oncology Institute's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.
Biodesix received 25 more outperform votes than Oncology Institute when rated by MarketBeat users. Likewise, 74.36% of users gave Biodesix an outperform vote while only 66.67% of users gave Oncology Institute an outperform vote.
36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by insiders. Comparatively, 69.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Biodesix beats Oncology Institute on 10 of the 16 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
This page (NASDAQ:TOI) was last updated on 2/22/2025 by MarketBeat.com Staff
